A switch in time saves more than nine

Published: May, 2006

Two popular statins, Pravachol and Zocor, go generic in the summer of 2006, paving the way for significant savings.

Bargain hunters, start your engines! The cost of lowering cholesterol is dropping dramatically for anyone willing to switch from a brand-name statin to a generic version. Pravachol lost its patent protection in April, while Zocor loses its protection in late June. Several companies are poised to sell generic versions of pravastatin (the main ingredient in Pravachol) and simvastatin (the main ingredient in Zocor) at prices lower than what the brand names command. These newcomers join lovastatin — the generic form of Mevacor — which has been on the market since 2001.

To continue reading this article, you must log in.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise

New subscriptions to Harvard Health Online are temporarily unavailable. Click the button below to learn about our other subscription offers.

Learn More »